Joslin Diabetes Center said its new Office of Commercialization and Ventures will collaborate with drug giants Eli Lilly and Co. and Pfizer Inc. to accelerate research aimed at predicting kidney failure and developing treatments for it.
The Joslin Office of Commercialization and Ventures was created in 2011 to work closely with the pharmaceutical industry to do research and develop drugs for the diabetes community. The Lilly-Pfizer collaboration is the first time two pharmaceutical companies have joined forces with Joslin, Joslin said.
As part of this cofunded research effort, Joslin said it will analyze samples from a unique biorepository collected and studied by Dr. Andrzej Krolewski, who heads Joslin’s Section on Genetics and Epidemiology.
One goal of the effort is to identify biomarkers for predicting kidney disease. Renal complications, also known as diabetic nephropathy, are one of the most life-threatening complications of diabetes, Joslin said in its press release.